|
WO2012015903A1
|
|
Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients
|
|
EP2525825A1
|
|
Combination therapy to treat autoimmune diseases
|
|
WO2011085081A2
|
|
Methods of selecting ms patients for antigen specific therapy
|
|
WO2010151420A1
|
|
Compositions and methods for treatment of insulin-dependent diabetes mellitus
|
|
WO2009102611A2
|
|
Methods of predicting responsiveness of ms patients to immune-based therapy
|
|
EP2032144A2
|
|
Methods and immune modulatory nucleic acid compositions for preventing and treating disease
|
|
CN101484176A
|
|
Methods and immune modulatory nucleic acid compositions for preventing and treating disease
|
|
AU2007260779A1
|
|
Polynucleotide therapy
|
|
CA2624615A1
|
|
Compositions and methods for treatment of autoimmune disease
|
|
US2007275899A1
|
|
Treatment of demyelinating autoimmune disease with modified ordered peptides
|
|
AU2004247018A1
|
|
Novel immunomodulating peptide
|
|
EP2329827A2
|
|
Methods and immune modulatory nucleic acid compositions for preventing and treating disease
|
